Abstract: A method of neuroinflammation and conditions associated therewith including chronic and acute conditions as well as specific and non-specific conditions. Oral dosage forms containing 640 mg micronized and non-micronized particulate metaxalone and excipients including alginic acid and propylene glycol alginate. The method includes inhibiting the monoamine oxidase A (MAO-A) enzyme as well as restoring/upregulating/increasing IL-13 and PGC-1?. The treated conditions, among others, include diabetic neuropathy, fibromyalgia, back pain, chronic pain induced depression, restless leg syndrome, anxiety, mood disorder, peripheral neuropathy, and herpetic neuralgia. The method further includes inducing or restoring homeostasis, restoring oxidative homeostasis, restoring basal phenotype from a neuroinflammatory state and improving neuroplasticity.